Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing Market Report 2025

The sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market size has grown rapidly in recent years. It will grow from $0.62 billion in 2024 to $0.68 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to the expansion of telemedicine platforms, increased adoption of electronic health records, rising insurance coverage, growth in community-based testing initiatives, and a higher number of diagnostic tests being conducted.

The sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market size is expected to see strong growth in the next few years. It will grow to $0.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to the increasing global prevalence of sexually transmitted infections, rising incidence of vaginal infections, a growing population of reproductive-age individuals, and overall population growth. Major trends in the forecast period include technological advancements, adoption of multiplex PCR panels, integration with telehealth platforms, connectivity with digital devices, and the development of self-collected testing kits.

The increasing number of sexual health screenings is expected to drive growth in the sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market in the coming years. Sexual health screenings involve medical tests that detect STIs and related conditions, enabling early diagnosis, treatment, and prevention of disease transmission. The rise in screenings is driven by the growing prevalence of STIs worldwide, highlighting the need for timely detection and treatment to prevent complications and limit the spread of infections. These screenings are critical for STI and vaginitis PCR testing, as they allow for early and accurate identification of infections, often even in asymptomatic individuals, supporting prompt treatment and infection control. For example, according to the UK Health Security Agency, a UK-based government body, 2,195,909 sexual health screening services for chlamydia, gonorrhea, syphilis, or HIV were conducted in June 2023, representing a 13.4% increase from the 1,936,455 tests performed in 2021. Consequently, the rise in sexual health screenings is fueling growth in the STI and vaginitis PCR testing market.

Key players in the STI and vaginitis PCR testing market are developing innovative solutions, such as multiplex PCR tests, to improve diagnostic accuracy, reduce testing time, and enable faster treatment decisions. Multiplex PCR tests are diagnostic tools that detect multiple pathogens simultaneously from a single sample using one PCR reaction. For instance, in November 2022, Cepheid Inc., a US-based molecular diagnostics company, launched the Xpert Xpress Multiplex Vaginal Panel (MVP), a rapid multiplex PCR test that detects DNA from the three primary causes of vaginal infections, bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis using a single vaginal sample. Delivering results in approximately 60 minutes, this test supports faster and more precise diagnosis in symptomatic women, facilitating targeted treatments that reduce treatment failures and unnecessary antibiotic use. Compatible with Cepheid’s GeneXpert systems, it enhances clinical decision-making and patient outcomes by quickly identifying co-infections at the point of care.

In June 2022, R-Biopharm Inc., a Germany-based developer of test solutions, acquired AusDiagnostics for an undisclosed amount. Through this acquisition, R-Biopharm aims to expand its molecular diagnostics capabilities, broaden its clinical diagnostics portfolio, enter new global market segments, and strengthen its position as a trusted provider of system solutions with enhanced diagnostic options. AusDiagnostics, based in Australia, manufactures in vitro diagnostic reagents and robotic systems for molecular-based syndromic testing, offering PCR testing for STIs and vaginitis.

Major players in the sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Hologic Inc., QIAGEN N.V., ARUP Laboratories Inc., Seegene Inc., LetsGetChecked Ltd., Sansure Biotech Inc., Visby Medical Inc., R-Biopharm AG, Savyon Diagnostics Ltd., altona Diagnostics GmbH, SpeeDx Pty Ltd., CERTEST BIOTEC S.L., ALPCO Diagnostics, Atila Biosystems Inc., Ridacom Diagnostics Ltd., Sinochips Diagnostics Co Ltd., Vitassay S.L., and Bioperfectus Technologies Co. Ltd.

North America was the largest region in the sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market in 2024. The regions covered in sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing is a highly accurate molecular diagnostic technique that amplifies and detects the genetic material of pathogens responsible for sexually transmitted and vaginal infections. This method allows for rapid identification of bacteria, viruses, and other microorganisms, enabling healthcare providers to diagnose infections effectively and customize treatments.

The primary test types for STI and vaginitis PCR testing include STI PCR panels and vaginitis PCR panels. STIs are infections caused by bacteria, viruses, fungi, or parasites, primarily transmitted through sexual contact, including vaginal, anal, and oral sex. These tests cover a broad spectrum of sexually transmitted and vaginal infections and are used by various end users such as hospitals and clinics, diagnostic laboratories, and homecare or at-home testing services.

The sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market research report is one of a series of new reports that provides sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market statistics, including sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing industry global market size, regional shares, competitors with a sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market share, detailed sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market segments, market trends and opportunities, and any further data you may need to thrive in the sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing industry. This sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market consists of revenues earned by entities by providing services such as clinical consultations, comprehensive screening tests, multiplex testing, treatment monitoring, and sample collection guidance. The market value includes the value of related goods sold by the service provider or included within the service offering. The sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market also includes sales of nucleic acid extraction kits, positive and negative control materials, automated PCR analyzers, and single-pathogen PCR test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.